基于机器学习的临床决策支持算法预测非小细胞肺癌抗PD-1治疗反应
本研究收集142例接受抗PD-1治疗的NSCLC患者临床数据,使用19个临床特征构建多种监督机器学习算法预测治疗反应。基于LightGBM的模型在发现集中AUC达0.788,优于传统多因素逻辑回归的0.759,并在独立验证集中验证。该算法为NSCLC患者抗PD-1治疗反应提供了临床决策支持工具。
要点
- PD-L1表达、肿瘤负荷和中性粒细胞与淋巴细胞比值可独立预测抗PD-1反应。
- 基于19个临床特征的LightGBM模型预测性能优于传统逻辑回归。
- 该机器学习算法可作为NSCLC抗PD-1治疗反应的临床决策支持工具。
核心结论
- 基于LightGBM算法的临床决策支持模型可预测NSCLC患者抗PD-1治疗反应。
研究设计与样本
- 回顾性收集142例接受抗PD-1治疗的NSCLC患者电子病历临床数据作为发现集。
- 使用19个临床特征训练LightGBM、XGBoost、多层神经网络、岭回归和线性判别分析等监督机器学习算法。
- 根据各算法预测性能选择最优模型,并在独立验证集中验证。
主要发现
- PD-L1表达、肿瘤负荷和中性粒细胞与淋巴细胞比值等因素可在发现集中独立预测抗PD-1反应。
- 基于19个临床特征的LightGBM算法AUC为0.788,优于单个临床特征和传统多因素逻辑回归的AUC 0.759。
关键数值与推荐
- LightGBM模型预测抗PD-1反应的AUC为0.788。
- 传统多因素逻辑回归预测抗PD-1反应的AUC为0.759。
临床怎么用
- 该算法可整合临床信息辅助识别可能从抗PD-1治疗中获益的NSCLC患者。
局限性
- 发现集样本量为142例,验证集样本量未在摘要中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Anti-programmed death (PD)-1 therapy confers sustainable clinical benefits for patients with non-small-cell lung cancer (NSCLC), but only some patients respond to the treatment. Various clinical characteristics, including the PD-ligand 1 (PD-L1) level, are related to the anti-PD-1 response; however, none of these can independently serve as predictive biomarkers. Herein, we established a machine learning (ML)-based clinical decision support algorithm to predict the anti-PD-1 response by comprehensively combining the clinical information. MATERIALS AND METHODS: We collected clinical data, including patient characteristics, mutations and laboratory findings, from the electronic medical records of 142 patients with NSCLC treated with anti-PD-1 therapy; these were analysed for the clinical outcome as the discovery set. Nineteen clinically meaningful features were used in supervised ML algorithms, including LightGBM, XGBoost, multilayer neural network, ridge regression and linear discriminant analysis, to predict anti-PD-1 responses. Based on each ML algorithm's prediction performance, the optimal ML was selected and validated in an independent validation set of PD-1 inhibitor-treated patients. RESULTS: Several factors, including PD-L1 expression, tumour burden and neutrophil-to-lymphocyte ratio, could independently predict the anti-PD-1 response in the discovery set. ML platforms based on the LightGBM algorithm using 19 clinical features showed more significant prediction performance (area under the curve [AUC] 0.788) than on individual clinical features and traditional multivariate logistic regression (AUC 0.759). CONCLUSION: Collectively, our LightGBM algorithm offers a clinical decision support model to predict the anti-PD-1 response in patients with NSCLC.
引用
- Ahn BC, So JW, Synn CB, et al. Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer. Eur J Cancer. 2021. PMID: 34182269. doi:10.1016/j.ejca.2021.05.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。